AEON Biopharma, Inc. (AEON)

AEON Biopharma was planning to go public, but the IPO has been withdrawn.
Stock Price: $14.00 - $16.00
Current IPO price range

Company Description

AEON Biopharma is a clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions.

ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus, Inc under the name Jeuveau. Botulinum toxins have proven to be a highly versatile therapeutic biologic, with over 230 therapeutic uses documented in published scientific literature and 10 approved therapeutic indications in the United States.

Our initial development programs for ABP-450 are directed at migraine, cervical dystonia and gastroparesis. Our Investigational New Drug application for ABP-450 as a preventative treatment for migraine was accepted by the FDA in the fourth quarter of 2020 and we initiated enrolling patients for our Phase 2 clinical study in the first quarter of 2021.

We plan to announce topline data related to our migraine study in the second half of 2022. Our IND application for ABP-450 as a treatment for cervical dystonia was accepted by the FDA in the third quarter of 2020 and we initiated our Phase 2 clinical study in the first quarter of 2021.

We plan to announce topline data in early 2022. In December 2020, we initiated a preclinical gastroparesis study. We expect to complete this preclinical study in the third quarter of 2021.

AEON Biopharma, Inc.
Country United States
Founded 2012
Industry Pharmaceutical Preparations
Sector Biotechnology
Employees 6
CEO Marc Forth

Contact Details

Address:
4040 MacArthur Blvd., Suite 260
Newport Beach, CA 92660
United States
Phone (949) 354-6499
Website aeonbiopharma.com

Stock Details

Ticker Symbol AEON
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1622667

Key Executives

Name Position
Marc Forth Chief Executive Officer and Director Nominee
Chris Carr Chief Financial Officer
Chad Oh, M.D. Chief Medical Officer
Simone Blank Director, Chair
Jost Fischer Director, Chairman Elect
Robert E. Grant Director
Vikram Malik Director
Darren O\'Brien Director

Latest SEC Filings

Date Type Title
Dec 29, 2021 RW Registration Withdrawal Request
Oct 7, 2021 S-1/A General form for registration of securities under the Securities Act of 1933
Oct 6, 2021 S-1/A General form for registration of securities under the Securities Act of 1933
Oct 4, 2021 S-1/A General form for registration of securities under the Securities Act of 1933
Sep 17, 2021 S-1 General form for registration of securities under the Securities Act of 1933
Sep 13, 2021 DRS/A Draft Registration Statement
Jul 20, 2021 DRS/A Draft Registration Statement
Jun 7, 2021 DRS/A Draft Registration Statement
May 13, 2021 D/A Notice of Exempt Offering of Securities
Aug 31, 2020 D Notice of Exempt Offering of Securities